211 related articles for article (PubMed ID: 31431290)
1. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
Igbinosa O; Dogho P; Osadiaye N
Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
[TBL] [Abstract][Full Text] [Related]
2. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
4. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
7. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
9. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
[TBL] [Abstract][Full Text] [Related]
10. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem-resistant
Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
Front Public Health; 2022; 10():983174. PubMed ID: 36091556
[TBL] [Abstract][Full Text] [Related]
12. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
[TBL] [Abstract][Full Text] [Related]
13. A Cohort Study of the Impact of Carbapenem-Resistant
Sabino S; Soares S; Ramos F; Moretti M; Zavascki AP; Rigatto MH
mSphere; 2019 Apr; 4(2):. PubMed ID: 30971443
[TBL] [Abstract][Full Text] [Related]
14. The Potential for Interventions in a Long-term Acute Care Hospital to Reduce Transmission of Carbapenem-Resistant Enterobacteriaceae in Affiliated Healthcare Facilities.
Toth DJA; Khader K; Slayton RB; Kallen AJ; Gundlapalli AV; O'Hagan JJ; Fiore AE; Rubin MA; Jernigan JA; Samore MH
Clin Infect Dis; 2017 Aug; 65(4):581-587. PubMed ID: 28472233
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
16. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
[TBL] [Abstract][Full Text] [Related]
18. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
19. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
[TBL] [Abstract][Full Text] [Related]
20. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
Antimicrob Resist Infect Control; 2017; 6():124. PubMed ID: 29225798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
